Nasal Spray Could End Flu Season Forever

Dutch biotech firm Leyden Laboratories, in partnership with Harvard University, is pioneering a novel nasal spray designed to combat influenza. This innovative spray contains a broad-spectrum antibody engineered to trap flu viruses within the nasal passages, thereby preventing them from entering the body.

Preclinical studies demonstrated the spray's efficacy in mice and monkeys, successfully preventing infection. Subsequent trials involving 143 healthy volunteers indicated that the spray is safe for use, with participants maintaining elevated antibody levels in their noses through twice-daily applications.

The antibody has proven effective in laboratory settings against both human and certain animal flu strains. This broad activity is particularly significant given the continuous mutation of influenza viruses, which necessitates annual vaccine reformulations and often results in incomplete protection.

By delivering antibodies directly to the nose, the primary entry point for most flu infections, this experimental spray holds the potential to provide extensive and rapid protection. Unlike current vaccines, it may not require annual updates, offering a more consistent defense against the evolving virus.